<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149460</url>
  </required_header>
  <id_info>
    <org_study_id>40280</org_study_id>
    <nct_id>NCT01149460</nct_id>
  </id_info>
  <brief_title>Valacyclovir 1000 mg Tablet Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Valacyclovir 1000 mg Tablet and Valtrex Administered as 1 x 1000 mg Tablet in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the rate and extent of absorption of Teva
      Pharmaceuticals USA valacyclovir and GlaxoSmithKline, USA (Valtrex) valacyclovir,
      administered as 1 x 1000 mg tablet under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir</measure>
    <time_frame>Blood samples collected over 12 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir</measure>
    <time_frame>Blood samples collected over 12 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir</measure>
    <time_frame>Blood samples collected over 12 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir</measure>
    <time_frame>Blood samples collected over 24 hour period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test 1000 mg Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valtrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference Listed Valacyclovir 1000 mg Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Test 1000 mg Tablet</description>
    <arm_group_label>Valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Reference Listed Valacyclovir 1000 mg Tablet</description>
    <arm_group_label>Valtrex</arm_group_label>
    <other_name>Valtrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, non-smokers, 18 years of age and older.

          -  Capable of consent

        Exclusion Criteria

        Subjects to whom any of the following applies will be excluded from the study:

          -  Clinically significant illnesses or surgery within 4 weeks of the administration of
             study medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or
             over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening.

          -  BMI less than 19.0 or greater than or equal to 30.0 kg/m2.

          -  History of significant alcohol abuse within six months prior to the screening visit
             (more than fourteen units of alcohol per week [1 Unit = 150 mL of wine or 360 mL of
             beer or 45 mL of alcohol 40% alcohol]) or positive urine drug screen at screening.

          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine
             (PCP) and crack) within 1 year prior to the screening visit or positive urine drug
             screen at screening.

          -  History of allergic reactions to heparin, valacyclovir, acyclovir, or other related
             drugs.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days
             prior to the administration of the study medication.

          -  Use of an investigational drug or participation in an investigation study within 30
             days prior to the administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism or excretion of the drug.

          -  Any clinically significant history or presence of clinically significant neurological,
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or
             metabolic disease.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products (including natural food supplements, vitamins,
             garlic as a supplement) within 7 days prior to administration of study medication,
             except for topical products without systemic absorption.

          -  Difficulty to swallow study medication.

          -  Use of any tobacco products in the 90 days preceding drug administration.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             medical subinvestigator, could contraindicate the subjects participation in this
             study.

          -  A depot injection or an implant of any drug within 3 months prior to administration of
             study medication.

          -  Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or
             loss of whole blood (excluding the volume of blood that will be drawn during the
             screening procedures of this study) prior to administration of the study medication as
             follows:

          -  50 mL to 300 mL of whole blood within 30 days,

          -  301 mL to 500 mL of whole blood within 45 days, or

          -  more than 500 mL of whole blood within 56 days prior to drug administration.

          -  Intolerance to venipunctures.

          -  Clinically significant history of renal, hepatic or cardiovascular disease,
             tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible
             for this study.

          -  Unable to understand or unwilling to sign the Informed Consent Form.

          -  Breast-feeding.

          -  Positive urine pregnancy test at screening.

          -  Female subjects of childbearing potential having unprotected sexual intercourse with
             any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for
             at least 6 months) within 14 days prior to study drug administration. Acceptable
             methods of contraception:

          -  Intra-uterine contraceptive device (placed at least 4 weeks prior to study drug
             administration),

          -  Condom or diaphragm + spermicide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <results_first_submitted>August 18, 2010</results_first_submitted>
  <results_first_submitted_qc>August 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2010</results_first_posted>
  <last_update_submitted>August 18, 2010</last_update_submitted>
  <last_update_submitted_qc>August 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <organization>Teva Pharmaceuticals USA</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valacyclovir</title>
          <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
        </group>
        <group group_id="P2">
          <title>Valtrex®</title>
          <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valacyclovir</title>
          <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
        </group>
        <group group_id="B2">
          <title>Valtrex®</title>
          <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 12 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
          </group>
          <group group_id="O2">
            <title>Valtrex®</title>
            <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Valacyclovir</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.35" spread="139.10"/>
                    <measurement group_id="O2" value="350.86" spread="133.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means (T/R)</param_type>
            <param_value>111.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.54</ci_lower_limit>
            <ci_upper_limit>123.29</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 12 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
          </group>
          <group group_id="O2">
            <title>Valtrex®</title>
            <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Valacyclovir</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549.32" spread="137.87"/>
                    <measurement group_id="O2" value="551.77" spread="140.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means (T/R)</param_type>
            <param_value>100.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.34</ci_lower_limit>
            <ci_upper_limit>103.82</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 12 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
          </group>
          <group group_id="O2">
            <title>Valtrex®</title>
            <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Valacyclovir</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="552.17" spread="138.76"/>
                    <measurement group_id="O2" value="554.53" spread="140.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means (T/R)</param_type>
            <param_value>100.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.38</ci_lower_limit>
            <ci_upper_limit>103.78</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir</title>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
          </group>
          <group group_id="O2">
            <title>Valtrex®</title>
            <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration of Drug Substance in Plasma) - Acyclovir</title>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6485.51" spread="1469.43"/>
                    <measurement group_id="O2" value="6283.25" spread="1375.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means (T/R)</param_type>
            <param_value>103.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.87</ci_lower_limit>
            <ci_upper_limit>109.41</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir</title>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
          </group>
          <group group_id="O2">
            <title>Valtrex®</title>
            <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) - Acyclovir</title>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22514.36" spread="4316.76"/>
                    <measurement group_id="O2" value="22675.85" spread="4063.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means (T/R)</param_type>
            <param_value>99.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.14</ci_lower_limit>
            <ci_upper_limit>101.31</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir</title>
        <time_frame>Blood samples collected over 24 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Valacyclovir</title>
            <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
          </group>
          <group group_id="O2">
            <title>Valtrex®</title>
            <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) - Acyclovir</title>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22705.17" spread="4336.16"/>
                    <measurement group_id="O2" value="22887.99" spread="4065.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>ANOVA is to be used to identify the source contributions by factors including subjects, period, formulation and potential interactions. The geometric mean ratio together with the ANOVA residual mean error term are used to identify the statistical basis for the 90% confidence interval for the ratio of the population means (Test [T]/Reference[R]) of the identified metrics (e.g. AUC, Cmax).</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>99.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.04</ci_lower_limit>
            <ci_upper_limit>101.19</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the test (T) and reference (R) product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valacyclovir</title>
          <description>Test 1000 mg Tablet dosed in first period follwed by Reference Listed 1000 mg Valtrex® tablet in second period</description>
        </group>
        <group group_id="E2">
          <title>Valtrex®</title>
          <description>Reference Listed Valtrex® 1000 mg Tablet dosed in first period followed by Test 1000 mg Valacyclovir tablet in second period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low Hemoglobin Level</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain/Cramp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Loose/Soft Stools</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/Drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

